Silver Lining In Aranesp Trial Outshines Its Two Failed Endpoints
This article was originally published in The Pink Sheet Daily
Executive Summary
Unlike previous trials, TREAT did not show a statistically significant adverse effect on all-cause mortality or cardiovascular morbidity when patients were treated to a hemoglobin target of 13 g/dL.
You may also be interested in...
FDA Draws Upon New Authority To Mandate Elements OF ESA Labeling
FDA and the sponsors of erythropoiesis-stimulating agents were mostly able to reach an agreement on safety revisions to labeling of the anemia therapies, but the agency was forced to employ its new regulatory authority to resolve a couple points of continued disagreement
Aranesp Trial May Allay EPO Concerns Despite Failing On Primary Endpoint
Results from an Amgen trial showing that anemia therapy Aranesp has a neutral impact on survival in cancer patients receiving chemotherapy could assuage concerns over the safety profile of erythropoiesis-stimulating agents at high doses
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.